BioStem Technologies

Symbol: BSEM

BioStem Technologies (OTC: BSEM) a global corporation providing world-class technologies focused on regenerative medicines, pharmaceuticals and Blue technologies which improve the overall healthy lifespan of our consumers. We have a diversified technology portfolio aimed at maximizing shareholder value. The combination of our two technologies will be used to produce ground breaking new pharmaceuticals and blue technologies.

http://www.biostemtechnologies.com

View Current Offering

Raise Amount:
$15,000,000

 

BioStem Technologies Inc. Investor Contact

“I’m pleased to be working with such a diverse group of scientists, physicians, and entrepreneurs, motivated to provide the very best medical technologies to improve the Quality of Life for our patients and, as a result, driving shareholder value. Our mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products & services in the world!”

– Henry “Chip” Van Vurst. CEO & Chairman of the Board

We’re looking forward to sharing the value we see in our upcoming ventures with our shareholders. If you would like more information on the company or on the current offering, please contact:

Andrew Van Vurst
ir@biostemtech.com
(954)-380-8342

 

BioStem Technologies Inc. – Company Overview

BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products and services in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products and services. These technologies improve the Quality of Life for our patients and, as a result, drives shareholder value.

  • Pharmaceuticals: The U.S. represents the largest continental pharma market worldwide, valued in 2016 at nearly $446 billion. Our pharma division will operate several subsidiaries: API (“Active Pharmaceutical Ingredient”) Supply, NDA and ANDA Formulation, and Manufacturing of Drug Products.

    • API Supply – Qualified Pharma Ingredients, Inc. (‘QPI’), our joint venture subsidiary, will supply “pre-qualified” API’s to drug manufacturers and compounders. Pre-qualified API’s are tested for potency, purity and stability throughout the life cycle of the product. This model reduces pharmacy risk, creates cost savings, and generates revenue opportunities, all while establishing the highest level of patient safety. Completion of this plan allows us to expand utilizing our contract with a strategic partner for co-branding and marketing of their Continuous Quality Improvement program to promote to its network of 1,500 pharmacies.

    • NDA and ANDA Formulation – BioStem Pharmacuticals, Inc., a wholly owned subsidiary, will develop and formulate drug products into different dosage forms. BioStem Pharmaceuticals has developed a strategic alliance with a biosciences company which have identified initial projects starting in 2018.

    • Manufacturing – BioStem Pharmaceuticals 6,100 square foot manufacturing facility will have the ability to provide contract, liquid and small batch manufacturing.

The alliance between these operations allows BSEM to leverage internal resources and knowledge for the commercialization of our own Pharmaceutical and Regenerative Medicine products and services. The BioStem pharma team has more than 120 years of combined experience and diverse backgrounds in manufacturing, product development and sales. Additionally, this team has taken multiple new drugs through the FDA’s approval process which resulted in numerous successful product launches.

  • Regenerative Medicine: The Regenerative Medicine market is estimated at nearly $13.4 billion and is expected to grow at a Compound Annual Growth Rate of 25.76% between 2017-2025. Rising R&D initiatives to develop therapeutic options for chronic diseases” and “a growing demand for regenerative treatment options are the most significant drivers of the industry, according to Grand View Research. High, unmet medical needs have led to more government initiatives for drug development and discovery.

BioStem Technologies is in the process of negotiating the acquisition of an established Regenerative Medicine, research and product company. This acquisition target holds several patents in the field and presently performs stem cell banking, regenerative and therapeutic treatments. It also retains approved treatment licenses as well as licenses for the banking/storage of stem cells and transportation of biological material. This division is expected to generate revenue from first and third-party billing for storage/banking of stem cells, regenerative and therapeutic therapies, and its patented technologies.

 

BioStem Technologies, Inc. – Why Invest?

At BioStem Technologies, we believe that the increase in an aging population presents unique opportunities for innovative medical services and pharmaceutical technologies. Current statistics show an encouraging pattern of increased life expectancy will trigger increased consumption in healthcare spending and we believe the market has yet to realize the real profitability potential for Regenerative Medicine and Pharmaceutical products and services.

The Company’s mission is to make significant contributions to humanity and the environment, while at the same time providing a healthy return to its investors by:

  • Creating, acquiring and distributing technologies that improve the general quality of life for humans; helping them live better, feel better, and perform better, at work, at play and in their intellectual pursuits.

  • Innovating Health and Wellness Technologies through its R&D Pipeline.

  • Generating “biotech-level” returns for its investors with a significantly lower risk profile than other available biotech investments.

 

BioStem Technologies, Inc. – Operational Milestones

Infrastructure:   COMPLETE

Phase I of BioStem Technologies business plan established the corporate infrastructure. During the execution of this phase, the Company acquired all necessary licensing and formed strategic alliances with veteran industry professionals and companies.

  • Corporate Capital Restructuring

  • Build Out of Pharmaceutical Manufacturing Facility

  • Build Out of Pharmaceutical Repackaging Facility

  • FDA Establishment Registration – Manufacturing

  • FDA Establishment Registration – Repackaging

  • 4 Million Dollar Capital Raise Completed

Pharmaceuticals:

Phase II of BioStem Technologies business plan is currently underway. Qualified Pharma Ingredients, the Companies pharmaceutical ingredient supply business established all necessary licensing and is now developing a sales force along with its strategic business partnerships. The executive team will soon be moving into its state-of-the-art laboratory facility to begin development of contract formulation work to include filing of NDA and ANDA drug applications. Blue Tech Ind., a wholly owned subsidiary of BioStem Technologies, currently has pre-clinical trials being performed at University of Miami.

  • FDA Product Registrations for Active Pharmaceutical Ingredients

  • State Bonds and Licensing Established

  • Initial Sales Channel Established

  • First Pre-Clinical Trial Underway

  • Develop SOP’s (Standard Operating Procedures)- Manufacturing Facility

  • Hiring of Sales Team and Pharmaceutical Industry Experienced Staff

Regenerative Medicine:

Phase III, launching in Q1 of 2018, will begin with acquisition/development of Regenerative Medicine protocols and patented technologies. With the Companies experience in the Stem Cell and Regenerative Medicine sectors, we feel confident that we have identified the best market opportunity utilizing innovative published scientific data to separate BioStem Technologies from its competitors.

  • Acquire Regenerative Medicine Clinic Network

  • Acquire Regenerative Medicine Intellectual Property and Patents

  • Grow Patient Network

  • Onboard additional scientific advisors and scientific board members

  • Develop

Pipeline:

The 4th Phase of BioStem Technologies business plan will involve the commercialization of proprietary technologies developed throughout the initial phases of the Companies business plan.

  • Cell Proliferation Technology

  • BSEM17-115 (Potential New Drug Application for Wound Care)

  • BSEM17-120 (Potential New Drug Application for Bacterial Infection)

  • BSEM17-XXX

    • Master Licensing Program for the following applications:

      • Agriculture

      • Desalination

      • Waste Water Treatment

      • Clean Renewable Energy

      • Emission Reduction

 

BioStem Technologies, Inc. – Leadership

Chip Van Vurst, Chief Executive Officer and BioStem Board Chairman. Henry’s the visionary of BioStem Technologies, and has run a variety of businesses over the past three decades as owner or partner, including online retail, brick and mortar retail, TV content production and distribution, along with producing and licensing technologies to global manufactures such as Volvo. He has also served as lead negotiator in multiple deals with fortune 500 companies. Mr. Van Vurst also has a competitive and successful “team” life away from the office as a winning sports car driver. With multiple national championships under his belt, he has had personal experience in managing collaboration among peer level experts in order to win in a highly competitive, data and science-dependent environment. As a brain tumor survivor and a catastrophic near-fatal accident survivor, he leads the Company with a unique understanding of the patients’ perspective. With Mr. Van Vurst’s empathy for patients who seek healing, his passion for new product development, his personal experience with stem cell treatment success, and his broad experience in running multiple strategic business units simultaneously, he is ideally suited to lead BioStem Technologies.

Jason Matuszewski, Chief Financial Officer of BioStem, and is also a Director and Co-Founder. He began his engineering career at the age of 15 working as a data analysis engineer for top-tier auto racing teams, including the Turner Motorsports’ BMW team. It was on the racing circuit that he originally met the Van Vursts. He holds a B.S. in Mechanical Engineering and a minor in Business Administration from the highly ranked Milwaukee School of Engineering, and he is Six Sigma Black Belt certified. Mr. Matuszewski became interested in biotech after working with the Juvenile Diabetes Research Foundation, and he eagerly joined the Van Vursts in co-founding BioStem. As CFO, Mr. Matuszewski helped engineer the purchase and restructure of the public vehicle that is now listed as BSEM.

Andrew Van Vurst, Chief Operating Officer of and is also a Director and Co-Founder BioStem: At the age of 14, he entered Florida Atlantic University; at the age of 19, he joined the Marine Corps where he trained in Heavy-Helicopter Training Squadron-302, and was responsible for daily operations and inspections on the Sikorsky CH-53E. After a successful career in the Marines, Mr. Van Vurst continued his education through Landmark Worldwide, completing its advanced programs. During this time he co-founded an assets acquisitions company where he analyzed distressed companies, looking for opportunities to buy, break up, and sell the company assets at a higher value. In August of 2014, he co-founded BioStem Technologies.

Joe EspositoPresident of Qualified Pharma Ingredients: Mr. Espositio is one of the top pharmaceutical operations executives in the industry. He holds a BS in Chemistry and an MS in Organic Chemistry from Southern Connecticut State University. He was an award winning Chemist and Development Chemist for Uniroyal, and spent a decade in senior-and-executive management positions, running various pharmaceutical manufacturing operations. As President of the Pharmaceuticals unit, he is responsible for the development and formulation of all our pharmaceuticals and API repackaging products.

Dr. Brant Watson, member of the scientific advisory board and self-taught in biomedical research, became a faculty member in the Departments of Neurology and Biomedical Engineering at the University of Miami School of Medicine in 1980, and was promoted to full professor in 1998. He holds a B.A. in Physics and Mathematics from Miami University (Ohio) and a Ph.D. in Nuclear Physics from Florida State University in 1970. He is the author of 91 peer-reviewed articles in professional journals, 25 book chapters, and 110 meeting abstracts on a range of topics that include cancer cytology, ophthalmology and, chiefly, cerebrovascular diseases (stroke) and spinal cord injury. The common theme of his work is photochemically-induced free radical chemistry and lipid peroxidation to induce thrombosis of arteries and veins, and dissolution of such thrombi by photophysically induced nitric oxide. He is a named inventor on two U.S. Patents and has another application in development. Dr. Watson’s research was funded by the National Institute of Neurological Diseases and Stroke for 22 years.

Dr. Jennie Sandqvist member of the scientific advisory board is a leading neurologist in Sweden. She has a medical degree from Semmelweis Medical School in Hungary, with a specialty in neurology; she served as Chief of Neurology at the Karolinska University Hospital in Stockholm-Sweden for seven years, and is currently the Chief of Neurology at the Neurological Rehab Station in Stockholm.

Bob Watson is a member of the Company’s Board of Directors and a strategic advisor to the Board. He graduated from Columbia University in New York City, and spent his early career with Procter & Gamble and J. Walter Thompson Advertising Agency. Mr. Watson left corporate life in the early 1980s, led two start-ups and two turnarounds as CEO, and then spent a decade in Silicon Valley as a partner in CLB Associates, a leading strategic advisory firm that worked with the portfolio companies of the top venture capital firms in the Valley. Mr. Watson has spent the past 12 years as
the Managing Partner of Watson Strategic, a corporate strategy firm based in South Florida

Reverend Michael Beckwithis an American minister, author, and founder of the Agape International Spiritual Center in Culver City, California, which is a trans-denominational community with 9,000 members who study and practice what’s known as New Thought–Ancient Wisdom philosophy. Reverend Beckwith teaches the universal truth principles found in “New-Thought-Ancient Wisdom,” and he is a featured teacher in the film and book The Secret. He is also the co-founder of the Association for Global New Thought, and co-chair of the Season for Nonviolence.

Cathy Woynarowski, President of Dr. Dave’s Best and retains a BA in English from Albright College, a MBA in Finance from Tulane and a MST in Tax Research from San Diego State University. Cathy began her career with General Dynamics, San Diego (now Lockheed Martin) managing; Bid and Proposal Development/Negotiation with various government agencies (DOE, Air Force and DOD). She then transitioned into managing cross disciplined teams involved in-procurement, engineering, operations and quality assurance. After leaving General Dynamics, she served as the Financial Analyst responsible for month end, quarter end and year end closings, budgets, forecasting and financial modelling. Then completing her time with Hewlett-Packard developing predictive models for new European distribution centers, Logistics management and development of algorithms for international distribution centers for Just in time inventory management. For the last 13 years, Cathy has worn every hat under the Dr. Dave’s Best Brand, including Operations management, customer relations, logistics and order fulfillment.

Laura KleinPresident of beTEN as 13 years of healthcare related IT experience in senior management positions, four years of startup CEO experience, and early career experience working for Merck and Sun Microsystems. Ms. Klein has a B.S. from North Carolina State University, an M.S. from University of Georgia, and an M.B.A. from University of Miami. She is experienced in HIPAA and Sarbanes-Oxley compliance, quality assurance, call center operation, ecommerce, fulfillment, subscription-based and ad-based revenue models, and social networking, all of which are critical to BioStem’s business strategies. Ms. Klein is also the original creator of the Company’s “beTEN” platform, which is a patented, personalized, behavior change app and online program that is focused on facilitating wellness and weight management behavioral changes for consumers of all demographics.

 

BioStem Technologies, Inc. –FAQ’s

What is the minimum investment?

5,000 Units, which is equal to $25,000 USD

What is a “Unit”?

A “Unit” consists of one share of common stock of the Company and a warrant to purchase one share of Common Stock, exercisable at a price of $10.00 per Share, exercisable at any time within one year of issuance.

What is Common Stock?

Common stocks are one form of a piece of ownership of a corporation. They are the type of stock that most people are thinking of when they use the term “stock.” Since stocks are partial ownership of a corporation, they are also known as “shares.”

What is a “Warrant”?

A warrant is a derivative that allows the shareholder the right, but not the obligation, to buy a security “Common Stock” at a certain price before expiration.

How do I exercise my warrant?

You can exercise your warrant submitting a warrant option contract prior to 12 months from the date of your original investment.

When was BioStem Technologies founded?

The company was founded in August 2014, when it acquired an existing medical tourism company.

What is BioStem Technologies ticker symbol and where does the stock trade?

BioStem Technologies currently trades on the OTC Markets under the symbol, BSEM.

Whom should I contact about my stock certificates?

Please contact BSEM’s registrar and transfer agent:

Transfer Online, Inc.™
512 SE Salmon St.
Portland, OR 97214
info@transferonline.com
+1 (503) 227-2950

What is BSEM’s schedule for releasing quarterly results in 2018?

Here is the current calendar:

  • Q1 2017/ April 20, 2017 at 9AM EST

  • Q2 2017/ July 26, 2017 at 9:30AM EST

  • Q3 2017/October 17, 2017 at 9:30AM EST

What is BSEM’s CUSIP number?

It is 090684200.

How do I place my name on BSEM’s news release e-mail distribution list?

Click here for a link to the E-mail Alerts page to register.

What are the three distinct entities within BSEM and how do they complement one another?

The three operating divisions of BSEM are BioStem Pharmaceuticals, BioStem Technologies (Regenerative Medicine) and Blue Tech Industries (R&D).

  • BioStem Pharmaceuticals owns and operates, Qualified Pharma Ingredients, an API (active pharmaceutical ingredient) repackaging operation, supplying pharmacies and small batch manufactures with ingredients necessary to manufacture pharmaceutical products. In 2018, BSEM plans to expand its pharmaceutical business through contract formulation, NDA and ANDA submissions and small batch manufacturing at its state-of-the-art 6,100 sq. ft. facility.

  • BioStem Technologies Inc., the companies Regenerative Medicine division, is in the process of negotiating the purchase of an established Regenerative Medicine, research and product company. This acquisition target holds several patents in the field and presently performs stem cell banking, regenerative and therapeutic treatments. It also retains approved treatment licenses as well as licenses for the banking/storage of stem cells and transportation of biological material. This division is expected to generate revenue from first and third-party billing for storage/banking of stem cells, regenerative and therapeutic therapies, and its patented technologies.

  • Blue Tech Ind., the Research and Development arm of BSEM performs studies and trials, gathering data and scientific proof of concept prior to commercializing patents and IP.

The alliance between these operations allows BSEM to leverage internal resources and knowledge for the commercialization of our own Pharmaceutical and Regenerative Medicine products and services. The BioStem pharma team has more than 120 years of combined experience and diverse backgrounds in manufacturing, product development and sales. Additionally, this team has taken multiple new drugs through the FDA’s approval process which resulted in numerous successful product launches.

Looking now at your mobile app – “Ten Wellness and Weight Management” – how does it work and what is the benefit to your patients, customers and your shareholders? Is there a cost? Can anyone download it and use it?

Yes, the beTen Wellness platform can be downloaded from the Apple and Android app store for $19.95. If the user is interested in either tracking overall wellness or changing their behavior around health and wellness, he or she will be able to use the app to record what they eat and do daily in order to receive a score based on their personal inputs. After two to four weeks of use this data will help the MFT cannabis coaches recommend beneficial tweaks in a person’s prescriptions. Tremendously important data for helping our clients achieve optimal health!

Your revenue to market cap suggests that if all goes to plan, shareholders may be rewarded by investing now. So let me ask you plainly, why invest in BSEM and indeed is everything on schedule?

We’re in a fast moving and very dynamic industry, as you well know. We strongly believe that by concentrating upon executing fully each division’s business plan we have a good chance of blowing way past our projections.

With such exciting potential gains comes risk, however, so, again, nothing can be guaranteed, and I’m not allowed to make investment recommendations.

Where can those considering investment get additional information?

You may contact BSEM’s Investor Relations Dept.:
BioStem Technologies, Inc.
Investor Relations
4749 NE 11th Ave
Oakland Park, FL 33334
954-380-8342